Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Atara Biotherapeutics ( (ATRA) ) has issued an announcement.
On April 30, 2026, Atara Biotherapeutics received notice from Nasdaq that it no longer meets the $50 million minimum market value of listed securities required for continued listing on the Nasdaq Global Select Market. The company has until October 27, 2026, to regain compliance by maintaining a market value of at least $50 million for at least 10 consecutive business days, during which time its shares will continue trading under the ATRA ticker.
Atara plans to monitor its market value and may consider options such as transferring to the Nasdaq Capital Market, though it has not committed to any specific action and there is no assurance it will regain compliance. If the company fails to meet the requirement by the deadline, its securities will be subject to delisting, a move that could be appealed to a Nasdaq Hearings Panel and would carry significant implications for investor liquidity and the company’s visibility in public markets.
The most recent analyst rating on (ATRA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
The score is weighed down primarily by weak financial quality (negative free cash flow and negative equity) and significant regulatory uncertainty around EBVALLO. Technicals are only modestly supportive in the very near term, while valuation support is limited due to a negative P/E and no dividend.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a biotechnology company whose common stock is listed on the Nasdaq Global Select Market under the symbol ATRA. The company operates in the biopharmaceutical sector, where its valuation and continued access to public capital markets are closely tied to Nasdaq’s listing standards and investor sentiment around its securities.
Average Trading Volume: 225,970
Technical Sentiment Signal: Sell
Current Market Cap: $40.6M
Learn more about ATRA stock on TipRanks’ Stock Analysis page.